Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
Key claim: A single-center randomized phase 2 trial is evaluating metronomic oral decitabine-cedazuridine combined with venetoclax in relapsed/refractory AML, higher-risk MDS, and high-risk/accelerated-phase MPN.
Abstract
This is a single-center randomized phase 2 open-label clinical trial.
Why this matters
Advanced-phase MPN and transformed disease remain among the most therapeutically barren MPN subtypes, and each new HMA + BCL-2 permutation tested there sharpens the reference set for what dosing schedules and combinations are worth pursuing. A metronomic (low-dose continuous) oral HMA schedule paired with venetoclax is a meaningful refinement of an already-adopted backbone, potentially altering tolerability and cytopenia profiles in a frail, heavily pretreated population that spans R/R AML, HR-MDS, and high-risk/AP MPN. It reinforces the cross-subtype convergence of R/R myeloid disease onto oral HMA + BCL-2 scaffolds regardless of underlying subtype.